专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022129947A1 MODIFIED SARS VIRUS SPIKE PROTEIN SUBUNIT 审中-公开
公开(公告)号：WO2022129947A1
公开(公告)日：2022-06-23
申请号：PCT/GB2021/053366
申请日：2021-12-17
申请人： IMPERIAL COLLEGE INNOVATIONS LIMITED , THE FRANCIS CRICK INSTITUTE LIMITED
发明人： TEDDER, Richard , MCCLURE, Myra , CHEREPANOV, Petr
IPC分类号： G01N33/68
摘要： The present invention provides a modified SARS-CoV spike protein S1 subunit (S1) polypeptide, having a modified amino acid sequence relative to a wild-type S1 sequence (SEQ ID NO: 1); a. the modified S1 polypeptide comprising at least one amino acid residue change located within a tetrapyrrole binding pocket for binding to a tetrapyrrole compound; b. wherein said at least one amino acid change is at a location on the modified S1 polypeptide sequence that corresponds to an amino acid location, of wild-type S1 (SEQ ID NO: 1), comprising: N99, 1101, W104, 1119, N121, V126, F175, M177, R190, F192, F194, I203, H207 and/or L226; and c. wherein the modified S1 polypeptide demonstrates lower binding affinity for said tetrapyrrole compound compared with wild-type S1.

2. 发明申请

WO2021234150A1 TUMOR MUTATIONAL BURDEN ASSOCIATED WITH SENSITIVITY TO IMMUNOTHERAPY IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA 审中-公开
公开(公告)号：WO2021234150A1
公开(公告)日：2021-11-25
申请号：PCT/EP2021/063659
申请日：2021-05-21
申请人： ASTRAZENECA AB
发明人： SI, Han , KUZIORA, Michael , HIGGS, Brandon W.
IPC分类号： C12Q1/6886
摘要： The disclosure generally relates to methods for treating urothelial carcinoma patients based on use of PD-L1 expression, blood-based tumor mutation burden, and identification of mutations in circulating tumor DNA associated with sensitivity or resistance to immunotherapy to predict overall survival in patients treated with durvalumab.

3. 发明申请

WO2021228988A1 BIOMARKERS FOR PREDICTING OVERALL SURVIVAL IN RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA 审中-公开
公开(公告)号：WO2021228988A1
公开(公告)日：2021-11-18
申请号：PCT/EP2021/062707
申请日：2021-05-12
申请人： ASTRAZENECA AB
发明人： LI, Weimin , YE, Jiabu , SI, Han , MORSLI, Nassim , ZHANG, Qu , WILDSMITH, Sophie
IPC分类号： C12Q1/6886
摘要： The present disclosure generally relates to methods for treating head and neck squamous cell carcinoma patients based on use of blood-based tumor mutation burden, PD-L1 expression, expression levels of immunomodulators, pro-angiogenesis markers and pro-inflammatory markers and/or identification of mutations in circulating tumor DNA.

4. 发明申请

WO2020079196A1 FLUID DISPENSER 审中-公开
公开(公告)号：WO2020079196A1
公开(公告)日：2020-04-23
申请号：PCT/EP2019/078298
申请日：2019-10-17
申请人： VECTAIR SYSTEMS LIMITED
发明人： DIX, Robert , NELSON, Rebecca , WALLER, Jonathan , GRAY, Michael , RIDOUT, Frederick
IPC分类号： B05B17/06 , B05B9/04 , A61L9/14 , B05B17/00
摘要： A dispenser capable of dispensing a fluid via a vertically-oriented piezo device comprises a reservoir in the form of a replaceable cartridge containing a fluid to be dispensed, a planar piezo element having front and rear surfaces and which in use is oriented with its plane vertical and which is drivable to vibrate and thereby dispense fluid from the front surface, and a pump to draw a predetermined amount, or dose, of fluid from the reservoir and to drive the dose of fluid at a predetermined above-atmospheric pressure to the rear surface of the piezo element for dispensing.

5. 发明申请

WO2020065249A1 THERAPEUTIC & COSMETIC USES OF BOTULINUM NEUROTOXIN SEROTYPE E 审中-公开
公开(公告)号：WO2020065249A1
公开(公告)日：2020-04-02
申请号：PCT/GB2019/051902
申请日：2019-07-04
申请人： IPSEN BIOPHARM LIMITED
发明人： PONS, Laurent
IPC分类号： A61K8/64 , A61Q19/08 , C07K14/33 , A61K38/48 , A61P17/00
摘要： The present invention is directed to a botulinum neurotoxin serotype E (BoNT/E) for use in treating a disorder, wherein the BoNT/E is administered to a human subject, and provides a maximum inhibition of neurotransmitter secretion from a target cell or tissue in ≤13 days after administration; and reduces to >25% inhibition of neurotransmitter secretion from the target cell or tissue at day 14 after administration.

6. 发明申请

WO2019048144A1 ELECTRICAL CONNECTOR 审中-公开
公开(公告)号：WO2019048144A1
公开(公告)日：2019-03-14
申请号：PCT/EP2018/071063
申请日：2018-08-02
申请人： REPL INTERNATIONAL LIMITED
发明人： PUDDU, Luigi , MONTE, Marcello
IPC分类号： H01R4/36 , F16B31/02 , H01R11/12
CPC分类号： H01R4/36 , F16B31/021 , H01R11/12
摘要： Electrical connectors for power supply cables typically include a connector body with a bore for the conductor and a shear bolt that extends transversely through the body into the bore. If the bolt is at least as wide as the bore then a short bolt head can be provided which accommodates any size of conductor without leaving a projection outside the body envelope. A sawtooth or buttress thread for the bolt gives the necessary mechanical strength.

7. 发明申请

WO2018158573A1 METHOD OF DETECTION 审中-公开
公开(公告)号：WO2018158573A1
公开(公告)日：2018-09-07
申请号：PCT/GB2018/050522
申请日：2018-02-28
申请人： IMPERIAL INNOVATIONS LIMITED
发明人： LARROUY-MAUMUS, Gerald , DORTET, Laurent , FILLOUX, Alain
IPC分类号： C12Q1/02 , C12Q1/04 , C12Q1/10
摘要： The present invention is directed to a method for detecting the presence or absence of a bacterium resistant to a cyclic cationic polypeptide antibiotic, comprising: (a) subjecting a test sample to mass spectrometry analysis and generating a mass spectrum output; wherein said test sample comprises a bacterial membrane or a fragment thereof, wherein the fragment comprises a non- Lipid A component; (b) identifying in said mass spectrum output a first defined peak indicative of the presence of Lipid A modified by phosphoethanolamine, wherein said first defined peak is a peak present in a mass spectrum output for Lipid A modified by phosphoethanolamine and wherein said first defined peak is absent from a corresponding mass spectrum output for native Lipid A; and (c) wherein the presence of said first defined peak indicates the presence of a bacterium resistant to a cyclic cationic polypeptide antibiotic, and wherein the absence of said first defined peak indicates the absence of a bacterium resistant to a cyclic cationic polypeptide antibiotic. This method is also used in a screening method to identify an inhibitor of cyclic cationic polypeptide antibiotic resistance in a bacterium. The matrix solution can contain 2,5-dihydroxybenzoic acid and aids in the selective extraction, co-crystallisation and ionisation of native Lipid A and/or modified Lipid A as an integral part of a bacterial membrane.

8. 发明申请

WO2018060739A8 ASSAY FOR DISTINGUISHING BETWEEN SEPSIS AND SYSTEMIC INFLAMMATORY RESPONSE SYNDROME 审中-公开
公开(公告)号：WO2018060739A8
公开(公告)日：2018-04-05
申请号：PCT/GB2017/052945
申请日：2017-09-29
申请人： THE SECRETARY OF STATE FOR HEALTH , UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
发明人： HALL, Judith , SZAKMANY, Tamas , SHAH, Sanjoy , KEMPSELL, Karen , BALL, Graham
IPC分类号： C12Q1/6883
摘要： There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: (i) determining the amount of one or more biomarker for sepsis, and one or more biomarker for SIRS in a sample obtained from a patient, wherein the one or more biomarker for sepsis is selected from the group consisting of: ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5, PPBP, and PF4; and the one or more biomarker for SIRS is selected from the group consisting of: PLA2G7, ARHGEF10L, MYCL, TGFBI, and GPR124, (ii) comparing the amount of the one or more biomarker for sepsis determined in said sample in (i) to a corresponding reference value representative of a healthy individual, (iii) comparing the amount of the one or more biomarker for SIRS determined in said sample in (i) to a corresponding reference value representative of a healthy individual; wherein the patient is diagnosed as having sepsis, when an increase is observed in the one or more biomarker for sepsis, and no increase is observed in the one or more biomarker for SIRS, in the sample obtained from the patient relative to the corresponding reference value; and wherein the patient is diagnosed as having SIRS, when an increase is observed in the one or more biomarker for SIRS, and no increase is observed in the one or more biomarker for sepsis, in the sample obtained from the patient relative to the corresponding reference value.

9. 发明申请

WO2018060739A3 ASSAY FOR DISTINGUISHING BETWEEN SEPSIS AND SYSTEMIC INFLAMMATORY RESPONSE SYNDROME 审中-公开
公开(公告)号：WO2018060739A3
公开(公告)日：2018-04-05
申请号：PCT/GB2017/052945
申请日：2017-09-29
申请人： THE SECRETARY OF STATE FOR HEALTH , UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
发明人： HALL, Judith , SZAKMANY, Tamas , SHAH, Sanjoy , KEMPSELL, Karen , BALL, Graham
IPC分类号： C12Q1/6883
摘要： There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: (i) determining the amount of one or more biomarker for sepsis, and one or more biomarker for SIRS in a sample obtained from a patient, wherein the one or more biomarker for sepsis is selected from the group consisting of: ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5, PPBP, and PF4; and the one or more biomarker for SIRS is selected from the group consisting of: PLA2G7, ARHGEF10L, MYCL, TGFBI, and GPR124, (ii) comparing the amount of the one or more biomarker for sepsis determined in said sample in (i) to a corresponding reference value representative of a healthy individual, (iii) comparing the amount of the one or more biomarker for SIRS determined in said sample in (i) to a corresponding reference value representative of a healthy individual; wherein the patient is diagnosed as having sepsis, when an increase is observed in the one or more biomarker for sepsis, and no increase is observed in the one or more biomarker for SIRS, in the sample obtained from the patient relative to the corresponding reference value; and wherein the patient is diagnosed as having SIRS, when an increase is observed in the one or more biomarker for SIRS, and no increase is observed in the one or more biomarker for sepsis, in the sample obtained from the patient relative to the corresponding reference value.

10. 发明申请

WO2018041916A1 IMPROVED PRE-EMERGENT HERBICIDE 审中-公开
标题翻译：改进的前期除草剂
公开(公告)号：WO2018041916A1
公开(公告)日：2018-03-08
申请号：PCT/EP2017/071807
申请日：2017-08-30
申请人： W. NEUDORFF GMBH KG
发明人： ARACHCHIGE, Chandanie W. , SAMARAJEEWA, Deepal
IPC分类号： A01N65/08 , A01N65/44 , A01N37/32 , A01N39/04 , A01N65/00 , A01N37/44 , A01P13/00
CPC分类号： A01N37/44 , A01N37/32 , A01N39/04 , A01N65/00 , A01N65/44
摘要： An environmentally compatible, pre-emergent herbicidal composition is provided that comprises a fertilizer seed meal and a transition metal chelate for enhancing the efficacy of the composition. The transition metals chelate can enhance, even synergistically effect the efficacy of the composition, while maintaining the selectivity of the herbicide.
摘要翻译：提供了环境相容的芽前除草组合物，其包含肥料种子粉和过渡金属螯合物以增强组合物的功效。过渡金属螯合物可以增强，甚至协同地影响组合物的功效，同时保持除草剂的选择性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式